CN117580580A - 用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇 - Google Patents

用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇 Download PDF

Info

Publication number
CN117580580A
CN117580580A CN202280045723.6A CN202280045723A CN117580580A CN 117580580 A CN117580580 A CN 117580580A CN 202280045723 A CN202280045723 A CN 202280045723A CN 117580580 A CN117580580 A CN 117580580A
Authority
CN
China
Prior art keywords
compound
subject
dose
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280045723.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·拉瑟
J·多尔蒂
J·M·乔纳斯
S·J·凯恩斯
H·贡都士-布鲁斯
A·E·布洛克
J·A·瓦尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CN117580580A publication Critical patent/CN117580580A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN202280045723.6A 2021-04-29 2022-04-29 用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇 Pending CN117580580A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181807P 2021-04-29 2021-04-29
US63/181,807 2021-04-29
PCT/US2022/026908 WO2022232494A1 (en) 2021-04-29 2022-04-29 Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female

Publications (1)

Publication Number Publication Date
CN117580580A true CN117580580A (zh) 2024-02-20

Family

ID=81748326

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280045723.6A Pending CN117580580A (zh) 2021-04-29 2022-04-29 用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇

Country Status (9)

Country Link
US (1) US20240216396A1 (https=)
EP (1) EP4329769A1 (https=)
JP (1) JP2024515830A (https=)
CN (1) CN117580580A (https=)
AU (1) AU2022267304A1 (https=)
CA (1) CA3217866A1 (https=)
IL (1) IL307980A (https=)
MX (1) MX2023012728A (https=)
WO (1) WO2022232494A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021006985A (es) * 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법

Also Published As

Publication number Publication date
AU2022267304A1 (en) 2023-11-02
WO2022232494A1 (en) 2022-11-03
EP4329769A1 (en) 2024-03-06
IL307980A (en) 2023-12-01
JP2024515830A (ja) 2024-04-10
CA3217866A1 (en) 2022-11-03
US20240216396A1 (en) 2024-07-04
MX2023012728A (es) 2023-11-08

Similar Documents

Publication Publication Date Title
CN117580580A (zh) 用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
TW202300156A (zh) 用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇
KR20240006026A (ko) 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
JP2023038310A (ja) １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
KR20220112803A (ko) 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
MD3347002T2 (ro) Tratamentul bolii Alzheimer într-o populație specifică de pacienți
US10278977B2 (en) Methods for treating hypersomnolence
CN101257898A (zh) 艾司佐匹克隆与o-去甲基文拉法辛的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
CN117098554A (zh) 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
Del Pozo et al. 274 vasculitic urticaria treated with omalizumab. Case report
TW202535357A (zh) 治療更年期及近更年期之方法
Kuschnir et al. 273 fetal loss in severe asthma and posterior healthy pregnancy and birth with the use of omalizumab—case report
Ibrahim et al. Sleep disorders
Xixis et al. Second-Generation
Swaab et al. Mechanisms underlying the behavioral teratogenic effects of chemicals on the developing brain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination